Home › RLT targets by cancer › Lung Cancer
Radioligand therapy · Lung Cancer

Radioligand Therapy Targets in Lung Cancer

Updated 2026-11 · Ranked from Human Protein Atlas, Open Targets, ClinicalTrials.gov and PubMed evidence

We screened every cell-surface protein with tumor immunohistochemistry data in lung cancer (including non-small cell (NSCLC) and small cell lung cancer (SCLC)). 4,335 show detectable protein staining. Established and emerging radioligand targets expressed in lung cancer include EPCAM, HER3 (ERBB3), CEA (CEACAM5) and EGFR. Below, we rank every candidate by tumor expression, internalization and clinical maturity.

Need a shortlist for your own lung cancer program? Rank every candidate against your isotope, organ-dose limits and novelty bar.

Rank lung cancer targets free

Established and emerging radioligand targets in lung cancer

Targets already pursued with radioligands or other targeted modalities that show protein expression in lung cancer:

TargetIHC in lung cancer% positiveInternalizes
EPCAMHigh (0.83)100%—
HER3 (ERBB3)High (0.70)100%yes
CEA (CEACAM5)High (0.67)91%—
EGFRHigh (0.63)80%yes
B7-H3 (CD276)High (0.61)100%—
STEAP2High (0.61)92%—
ITGB6Medium (0.47)83%—
ITGAVMedium (0.47)75%—
c-MET (MET)Medium (0.42)91%yes
TMEFF2Medium (0.30)64%—
Nectin-4 (NECTIN4)Medium (0.28)58%no
Claudin 18.2 (CLDN18)Medium (0.24)27%uncertain
TROP2 (TACSTD2)Medium (0.23)50%uncertain
Mesothelin (MSLN)Medium (0.22)33%yes
STEAP1Medium (0.21)27%—
SSTR2Low (0.17)42%yes
FAPLow (0.12)27%yes
HER2 (ERBB2)Low (0.09)18%yes
KITLow (0.06)8%no
CD20 (MS4A1)Low (0.03)8%uncertain
DLK1Low (0.03)8%—

Top cell-surface targets for lung cancer radioligand therapy

A data-driven screen of every protein annotated as cell-surface. It deliberately surfaces novel, unvalidated candidates, so confirm localization and expression before prioritizing any of them.

#TargetIHC in lung cancer% positiveInternalizesClinical stage
1EGFR
epidermal growth factor receptor
High (0.63)80%yesFDA-Approved
2GPR139
G protein-coupled receptor 139
High (1.00)100%yesDiscovery
3HER3 (ERBB3)
erb-b2 receptor tyrosine kinase 3
High (0.70)100%yesFDA-Approved
4IGF1R
insulin like growth factor 1 receptor
High (0.67)100%yesFDA-Approved
5AMFR
autocrine motility factor receptor
High (0.94)100%yesDiscovery
6S1PR1
sphingosine-1-phosphate receptor 1
High (0.52)82%yesFDA-Approved
7EPHB2
EPH receptor B2
High (0.70)100%uncertainFDA-Approved
8FZD6
frizzled class receptor 6
High (0.85)100%yesDiscovery
9NR3C2
nuclear receptor subfamily 3 group C member 2
High (0.69)100%uncertainFDA-Approved
10MST1R
macrophage stimulating 1 receptor
High (0.56)92%yesFDA-Approved
11FZD3
frizzled class receptor 3
High (0.80)100%yesDiscovery
12NOTCH2
notch receptor 2
High (0.61)100%yesClinical
13c-MET (MET)
MET proto-oncogene, receptor tyrosine kinase
Medium (0.42)91%yesFDA-Approved
14AGTRAP
angiotensin II receptor associated protein
High (0.76)100%yesDiscovery
15CCRL2
C-C motif chemokine receptor like 2
High (0.64)91%yesDiscovery
16APH1A
aph-1A gamma-secretase subunit
High (0.97)100%—FDA-Approved
17KCNG1
potassium voltage-gated channel modifier subfamily G member 1
High (0.77)100%—FDA-Approved
18LSR
lipolysis stimulated lipoprotein receptor
High (0.77)100%yesDiscovery
19CYSLTR2
cysteinyl leukotriene receptor 2
High (0.61)91%yesDiscovery
20HRH4
histamine receptor H4
High (0.61)91%yesClinical
21ADGRL1
adhesion G protein-coupled receptor L1
High (0.73)100%yesDiscovery
22MAOB
monoamine oxidase B
High (0.72)100%—FDA-Approved
23ITPR3
inositol 1,4,5-trisphosphate receptor type 3
High (0.72)100%yesDiscovery
24SEMA6A
semaphorin 6A
High (0.97)100%—Discovery
25NOTCH1
notch receptor 1
High (0.55)91%yesClinical

Internalizing receptors in lung cancer

Targets expressed in lung cancer that the literature reports internalize after ligand binding. Internalization traps the radionuclide inside the tumor cell, which matters most for β-emitters like 177Lu and for α-emitters like 225Ac:

EGFR · GPR139 · HER3 (ERBB3) · IGF1R · AMFR · S1PR1 · FZD6 · MST1R · FZD3 · NOTCH2 · c-MET (MET) · AGTRAP

Lung Cancer targets already in clinical development

Targets with a clinical-stage drug program (any modality) that are also expressed in lung cancer. Clinical precedent lowers development risk but usually means more competition:

EGFR · HER3 (ERBB3) · IGF1R · S1PR1 · EPHB2 · NR3C2 · MST1R · NOTCH2 · c-MET (MET) · APH1A · KCNG1 · HRH4

How these lung cancer targets are ranked

Candidates are limited to proteins annotated as cell-surface (UniProt via Open Targets), because a radioligand has to reach its target from circulation. They are ranked by Nuclens' radiopharmaceutical pre-screen: immunohistochemistry staining and patient-sample positivity in lung cancer, literature evidence of internalization and shedding, clinical maturity, and cancer association. It is a first-pass triage, not a substitute for wet-lab validation or dosimetry. For the full framework, see what makes a good radioligand therapy target and emerging radioligand targets beyond PSMA.

Rank lung cancer targets against your own criteria: isotope, organ limits, novelty.

Run a free lung cancer analysis

Radioligand therapy targets in other cancers

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Shortlist lung cancer targets for your program · 5 free analyses, no card Rank lung cancer targets free